Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins


BACKGROUND
Endovenous laser ablation and ultrasound-guided foam sclerotherapy are recommended alternatives to surgery for the treatment of primary varicose veins, but their long-term comparative effectiveness remains uncertain.

METHODS
In a randomized, controlled trial involving 798 participants with primary varicose veins at 11 centers in the United Kingdom, we compared the outcomes of laser ablation, foam sclerotherapy, and surgery. Primary outcomes at 5 years were disease-specific quality of life and generic quality of life, as well as cost-effectiveness based on models of expected costs and quality-adjusted life-years (QALYs) gained that used data on participants’ treatment costs and scores on the EuroQol EQ-5D questionnaire.

RESULTS
Quality-of-life questionnaires were completed by 595 (75%) of the 798 trial participants. After adjustment for baseline scores and other covariates, scores on the Aberdeen Varicose Vein Questionnaire (on which scores range from 0 to 100, with lower scores indicating a better quality of life) were lower among patients who underwent laser ablation or surgery than among those who underwent foam sclerotherapy (effect size [adjusted differences between groups] for laser ablation vs. foam sclerotherapy, −2.86; 95% confidence interval [CI], −4.49 to −1.22; P<0.001; and for surgery vs. foam sclerotherapy, −2.60; 95% CI, −3.99 to −1.22; P<0.001). Generic quality-of-life measures did not differ among treatment groups. At a threshold willingness-to-pay ratio of £20,000 ($28,433 in U.S. dollars) per QALY, 77.2% of the cost-effectiveness model iterations favored laser ablation. In a two-way comparison between foam sclerotherapy and surgery, 54.5% of the model iterations favored surgery.

CONCLUSIONS
In a randomized trial of treatments for varicose veins, disease-specific quality of life 5 years after treatment was better after laser ablation or surgery than after foam sclerotherapy. The majority of the probabilistic cost-effectiveness model iterations favored laser ablation at a willingness-to-pay ratio of £20,000 ($28,433) per QALY. (Funded by the National Institute for Health Research; CLASS Current Controlled Trials number, ISRCTN51995477.)
MINIMALLY INVASIVE TREATMENT OPTIONS such as endovenous laser ablation therapy and ultrasound-guided foam sclerotherapy are now recommended alternatives to surgery for the treatment of varicose veins.1-9 Medium-term follow-up studies suggest that laser ablation, foam sclerotherapy, and surgery result in equivalent recurrence rates and quality of life at 2 years and 3 years after treatment.10-12 At 5 years, quality of life appears to be similar among those who underwent laser ablation and those who underwent surgery,10,13-15 but limited comparative data are available on persons who underwent foam sclerotherapy.16 There is also a paucity of data on clinical recurrence rates, which has led to uncertainty regarding the cost-effectiveness of these treatments.

We performed the Comparison of Laser, Surgery, and Foam Sclerotherapy (CLASS) trial, a large, multicenter, randomized, comparative-effectiveness trial, to assess quality of life and cost-effectiveness associated with treatment for varicose veins at 6 months and 5 years after treatment.9,17,18 Here, we present the 5-year primary outcomes of the CLASS trial.

METHODS

STUDY OVERSIGHT

This study was conducted according to the protocol, available with the full text of this article at NEJM.org.9 Approval of the trial for all sites was obtained from the Scotland A Research Ethics Committee and the Medicines and Healthcare Products Regulatory Authority. Aberdeen University was responsible for initiation, management, and financial oversight of the research. The trial was overseen by a trial steering committee and an independent data and safety monitoring committee. Data analysis was performed by statisticians at the Centre for Healthcare Randomized Trials, University of Aberdeen. The project management group (see the Supplementary Appendix, available at NEJM.org) assumes responsibility for the accuracy and completeness of the data and the fidelity of the trial to the protocol.

PATIENTS

Patients who were eligible for treatment of varicose veins were recruited at 11 vascular surgery departments in the United Kingdom from November 2008 through October 2012. Inclusion criteria were an age of 18 years or older, the presence of primary symptomatic varicose veins greater than 3 mm in diameter in one or both legs, and reflux of the great saphenous or small saphenous veins of more than 1 second as measured by duplex ultrasonography. In participants with varicose veins in both legs, the more severely affected leg was designated as the study leg. Exclusion criteria were current deep-vein thrombosis, acute superficial-vein thrombosis, and additional anatomical and participant factors (listed in Table S1 in the Supplementary Appendix). Written informed consent was obtained from all participants.

RANDOMIZATION AND STUDY TREATMENT

We compared foam sclerotherapy, laser ablation (with subsequent foam sclerotherapy for residual varicosities, if necessary), and surgery. Participants underwent randomization with the use of a computer-generated randomization system, with balanced assignment to all treatment options available at each investigating center within two strata — stratum A, which included eight hospitals offering all three treatment options; and stratum B, which included three hospitals offering treatment only with foam sclerotherapy and surgery. Randomization was performed with the use of a minimization algorithm that included center, age (<50 years or ≥50 years), sex, reflux in the great or the small saphenous veins, and varicose veins in one or both legs. Because of the nature of the treatment, participants and assessors were aware of the group assignments.

The laser ablation, foam sclerotherapy, and surgical treatment methods have been described previously (Table S2 in the Supplementary Appendix).9 Laser ablation was performed, with the patient under local anesthesia, in a treatment room in the case of 90.5% of legs treated and in an operating theater in the case of 9.5%. Surgery was performed while the patient was under general anesthesia in an ambulatory care setting. In patients with varicose veins in both legs, both legs were treated with the same method when possible.

FOLLOW-UP AND OUTCOME MEASURES

Five years after treatment, all participants were invited to attend a 5-year follow-up clinic appointment. If they did not attend, they were mailed participant questionnaires followed by two mailed...
reminders. The medical records of all participants were reviewed by a trial nurse to determine the timing and nature of any treatment the participants received after the initial procedure.

The primary outcome measures at 5 years were participant-reported disease-specific quality of life measured with the Aberdeen Varicose Vein Questionnaire (AVVQ)\(^{19-22}\); participant-reported generic quality of life measured with the EuroQol EQ-5D (EQ-5D) questionnaire\(^{23}\) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36)\(^{24}\) (physical-component and mental-component scores); and 5-year model-based cost-effectiveness calculated as cost per quality-adjusted life-year (QALY) gained. The AVVQ consists of 12 questions and a set of mannequin legs on which participants are asked to draw their veins. AVVQ scores range from 0 to 100, with lower scores indicating a better quality of life. The EQ-5D has five dimensions, and scores range from −0.594 to 1.000, with higher scores indicating a better quality of life. The SF-36 consists of eight domains and yields two summary scores (the physical component score and the mental component score), each of which ranges from 0 to 100, with higher scores indicating greater well-being. Our previously constructed Markov model was updated with observed rates of recurrence and further treatment, and the cost and utility impact (i.e., the effect of recurrence and further treatment on the cost and effects outcomes) of these events were derived from the 5-year analysis of individual patient data.\(^{17,18}\) (Additional details on the Markov model and on all scales and scores included in this article are provided in Fig. S1 and Table S3 in the Supplementary Appendix.)

Secondary outcomes were quality of life measured with the EQ-5D visual-analogue scale (VAS; scores range from 0 to 100, with higher scores indicating better health) and the SF-36 domain scores; trial-based incremental cost-effectiveness, assessed with the use of data on costs and QALYs for individual patients; clinical success as measured by the presence of varicose veins assessed by the participant and nurse using a VAS that ranged from 0 (no varicose veins) to 10 (the worst varicose veins the patient can imagine) and the Venous Clinical Severity Score (a score consisting of nine categories relating to symptoms or signs of venous disease and one category relating to the use of compression; scores range from 0 [no venous disease] to 30 [most severe venous disease]; additional procedures for treatment of varicose veins and the associated costs; and participant satisfaction and willingness to repeat and recommend the treatment. In addition, the effect of the treatments on truncal-vein ablation, as assessed by duplex ultrasonography, was determined in a subgroup of participants.

**STATISTICAL ANALYSIS**

We performed intention-to-treat analyses for the following prespecified comparisons: a comparison of foam sclerotherapy with surgery using data from participants in strata A and B, a comparison of laser ablation with surgery using data from patients in stratum A, and a comparison of laser ablation with foam sclerotherapy using data from patients in stratum A. The principal analyses of the trial were performed when all participants had completed a 5-year follow-up and were conducted according to a prespecified statistical plan (available with the protocol at NEJM.org), with the use of Stata software, version 14 (StataCorp). The study database was locked on August 15, 2017, before the analyses were performed.

To determine the treatment effect size, we compared the groups using general linear models with adjustments for the minimization covariates and, when possible, with adjustments for baseline scores on the AVVQ, EQ-5D, SF-36, and Venous Clinical Severity Score. Mixed models with a compound-symmetry covariance matrix and with the center fitted as a random effect were used to analyze the continuous outcomes. All the available data were used to estimate effect sizes and interactions, and any missing data were assumed to be missing at random. Details of available interval quality-of-life data are included in Table S4 in the Supplementary Appendix. Sensitivity analyses were performed to compare the demographic characteristics of patients who completed the 5-year follow-up with those of patients who did not complete the 5-year follow-up.\(^{25}\) As an additional sensitivity analysis, multiple imputation with chained equations was performed for the primary quality-of-life outcomes at 5 years. We analyzed truncal-vein ablation rates and treatment satisfaction using ordinal logistic regression.
Details of the original power calculation were published previously. The initial planned sample size was 1015 patients but was later revised to 779 on the basis of results of a review by the data and safety monitoring committee. The objective was to have at least 90% power to detect a difference of 0.25 standard deviation in the AVVQ score for the comparison of foam sclerotherapy with surgery at 6 months; this difference was considered to be clinically significant. The sample size calculations accounted for an estimated 30% loss to follow-up at 5 years. A statistical significance level of 5% was adjusted to account for multiple comparisons (P<0.0033) for primary outcomes. Confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible.

Both the model-based and trial-based economic analyses included a three-way comparison of foam sclerotherapy, surgery, and laser ablation with participant data from stratum A and a two-way comparison (foam sclerotherapy vs. surgery) with data from Strata A and B. The statistical methods for the economic analyses are provided in Tables S5 and S6 and the text in the Supplementary Appendix.

Results

Patients and treatment

We recruited 798 participants, of whom 595 (75%) completed the participant questionnaires at 5 years, including questionnaires assessing quality of life, presence of varicose veins, satisfaction with treatment, and further treatment they had received (Fig. 1). The baseline demographic and clinical data are shown in Table 1. A sensitivity analysis showed that participants who did not complete the 5-year follow-up questionnaires were younger than those who did complete the questionnaires (mean age, 44.5 years vs. 51.0 years; P<0.001) (Table S7 in the Supplementary Appendix).

Data on 766 participants (96%) were extracted from case notes. In total, 467 participants (59%) attended a clinic visit at which a nurse assessed the secondary outcomes of Venous Clinical Severity Score and extent of varicose veins; 389 participants (49%) underwent duplex ultrasonography, which was performed at seven centers.

Primary outcomes

Table 2 summarizes results for the four primary quality-of-life outcome measures. All groups showed improvement from baseline in quality of life. The AVVQ scores in the laser ablation and surgery groups were significantly lower (indicating better quality of life) than the scores in the foam sclerotherapy group (effect size for laser ablation vs. foam sclerotherapy, −2.86; 95% confidence interval [CI], −4.49 to −1.22; P<0.001; and effect size for surgery vs. foam sclerotherapy, −2.60; 95% CI, −3.99 to −1.22; P<0.001). A sensitivity analysis revealed no significant differences in the baseline or 6-month AVVQ scores between patients who did not complete the 5-year follow-up and those who completed the 5-year follow-up. The other quality-of-life measures did not differ significantly among the treatment groups. Sensitivity analyses of the quality-of-life measures with the use of multiple imputation with chained equations revealed similar results. (Also see Tables S8 and S9 in the Supplementary Appendix.)

The updated Markov model results are shown in Table 3. In the three-way model-based cost-effectiveness analysis, laser ablation cost £460 ($654 in U.S. dollars) more than foam sclerotherapy and generated a nonsignificant gain in QALYs (0.113), for an incremental cost-effectiveness ratio of £4,064 ($5,778) per QALY gained. Surgery cost £289 ($411) more than laser ablation and generated marginally fewer QALYs; as a result, from a cost-effectiveness standpoint, laser ablation was deemed to be superior to surgery. At a threshold willingness-to-pay ratio of £20,000 ($28,433) per QALY, 77.2% of the probabilistic model iterations favored laser ablation (Fig. 2).

Figure S2 in the Supplementary Appendix shows the uncertainty surrounding the joint incremental costs and effects for the three-way comparison. In the two-way comparison of foam sclerotherapy with surgery, surgery cost an additional £737 ($1,048) per patient, for a mean QALY gain of 0.042, resulting in an incremental cost-effectiveness ratio of £17,554 ($24,956) (Table 3). Figure S3 in the Supplementary Appendix shows the uncertainty surrounding the joint incremental costs and effects for the two-way comparison.

At the willingness-to-pay threshold of £20,000 ($28,433) per QALY, 54.5% of the model iterations favored surgery (Fig. S4 in the Supplementary Appendix).
Figure 1. Screening, Randomization, and Follow-up.
A total of 13 participants (1.6%) were excluded after randomization because they had veins greater than 15 mm in diameter (5 participants), recurrent varicose veins (3 participants), or coexisting conditions or absence of reflux (5 participants). Participants who were assigned to treatment with laser ablation or foam sclerotherapy had the option of retreatment with foam sclerotherapy for any residual varicosities at or after the 6-week follow-up assessment. One site performed concurrent phlebectomies at the time of laser therapy.
SECONDARY OUTCOMES
There were no major differences between groups in SF-36 subscales or EQ-5D VAS scores. With regard to patient satisfaction, the majority of participants were willing to repeat the same treatment and to recommend the treatment they had received to a friend (Tables S10 and S11 in the Supplementary Appendix).

At 5 years, 58% of the patients who had undergone laser ablation, 54% who had undergone surgery, and 47% who had undergone foam sclerotherapy reported having no varicose veins (odds ratio for foam sclerotherapy vs. laser ablation, 0.59; 95% CI, 0.41 to 0.85). Overall, 11% of the patients in the laser ablation group, 14% in the foam sclerotherapy group, and 7% in the surgery group had further treatment.

The mean (±SD) extent of varicose veins as

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Laser Ablation Group (N = 210)</th>
<th>Foam Sclerotherapy Group (N = 286)</th>
<th>Surgery Group (N = 289)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age — yr</td>
<td>49.7±14.4</td>
<td>49.0±13.3</td>
<td>49.2±13.7</td>
</tr>
<tr>
<td>Female sex — no. (%)</td>
<td>120 (57.1)</td>
<td>162 (56.6)</td>
<td>161 (56.4)</td>
</tr>
<tr>
<td>Body-mass index†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>27.0±4.6</td>
<td>27.1±4.4</td>
<td>27.7±4.7</td>
</tr>
<tr>
<td>Data missing — no. (%)</td>
<td>14 (6.7)</td>
<td>17 (5.9)</td>
<td>28 (9.7)</td>
</tr>
<tr>
<td>Involvement of one leg — no. (%)</td>
<td>153 (72.9)</td>
<td>215 (75.2)</td>
<td>196 (67.8)</td>
</tr>
<tr>
<td>Deep-vein thrombosis — no. (%)</td>
<td>6 (2.9)</td>
<td>4 (1.4)</td>
<td>9 (3.1)</td>
</tr>
<tr>
<td>Saphenous vein involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Great saphenous vein — no. (%)</td>
<td>182 (86.7)</td>
<td>232 (81.1)</td>
<td>239 (82.7)</td>
</tr>
<tr>
<td>Widest diameter — mm‡</td>
<td>9.1±3.1</td>
<td>8.4±2.7</td>
<td>8.7±2.8</td>
</tr>
<tr>
<td>Reflux above the knee only — no. (%)§</td>
<td>151 (96.2)</td>
<td>169 (93.9)</td>
<td>180 (98.4)</td>
</tr>
<tr>
<td>Reflux above and below the knee — no. (%)¶</td>
<td>6 (3.8)</td>
<td>11 (6.1)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>Small saphenous vein — no. (%)</td>
<td>14 (6.7)</td>
<td>21 (7.3)</td>
<td>21 (7.3)</td>
</tr>
<tr>
<td>Widest diameter — mm</td>
<td>7.1±1.7</td>
<td>7.6±2.2</td>
<td>7.7±3.3</td>
</tr>
<tr>
<td>Deep-vein reflux — no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presence of deep-vein reflux‖</td>
<td>28 (13.3)</td>
<td>47 (16.4)</td>
<td>25 (8.7)</td>
</tr>
<tr>
<td>Data missing</td>
<td>6 (2.9)</td>
<td>6 (2.1)</td>
<td>8 (2.8)</td>
</tr>
<tr>
<td>CEAP classification — no. (%)**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C2, varicose veins &gt;3 mm in diameter</td>
<td>113 (54.1)</td>
<td>169 (59.1)</td>
<td>147 (51.2)</td>
</tr>
<tr>
<td>C3, edema</td>
<td>28 (13.4)</td>
<td>35 (12.2)</td>
<td>39 (13.6)</td>
</tr>
<tr>
<td>C4, skin and subcutaneous changes</td>
<td>56 (26.8)</td>
<td>74 (25.9)</td>
<td>90 (31.4)</td>
</tr>
<tr>
<td>C5 or C6, skin changes with healed or active venous ulcer</td>
<td>12 (5.7)</td>
<td>8 (2.8)</td>
<td>11 (3.8)</td>
</tr>
<tr>
<td>Data missing</td>
<td>1 (0.5)</td>
<td>2 (0.7)</td>
<td></td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. CEAP denotes clinical, etiologic, anatomical, and pathophysiological.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ P = 0.008 for the comparison between the laser ablation group and the foam sclerotherapy group.
§ The percentages are based on the total numbers of participants with great saphenous vein involvement.
¶ P = 0.02 for the comparison between the foam sclerotherapy group and the surgery group.
‖ P = 0.006 for the comparison between the foam sclerotherapy group and the surgery group.
** The percentages for the individual classifications are based on the total number of participants in each treatment group minus those for whom data are missing.
Table 2. Estimates of Treatment Effect on Primary Quality-of-Life Outcomes.*

<table>
<thead>
<tr>
<th>Quality-of-Life Measure</th>
<th>Mean Score</th>
<th>Effect Size (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Laser Ablation (N = 210)</td>
<td>Foam Sclerotherapy (N = 286)</td>
</tr>
<tr>
<td>AVVQ§ Baseline</td>
<td>17.7±8.9</td>
<td>17.3±9.3</td>
</tr>
<tr>
<td>Marginal effect¶</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6 months</td>
<td>7.8±8.2</td>
<td>9.0±7.9</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5 years</td>
<td>8.6±8.5</td>
<td>11.0±9.9</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Between-center variance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>EQ-5D** Baseline</td>
<td>0.795±0.173</td>
<td>0.806±0.176</td>
</tr>
<tr>
<td>Marginal effect¶</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6 months</td>
<td>0.903±0.171</td>
<td>0.895±0.174</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5 years</td>
<td>0.86±0.220</td>
<td>0.84±0.209</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Between-center variance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>SF-36 PCS†† Baseline</td>
<td>49.2±8.2</td>
<td>49.4±8.5</td>
</tr>
<tr>
<td>Marginal effect¶</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6 months</td>
<td>52.6±7.3</td>
<td>52.4±8.5</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5 years</td>
<td>50.0±10.1</td>
<td>50.0±9.2</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Between-center variance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>SF-36 MCS†† Baseline</td>
<td>52.2±8.7</td>
<td>52.4±8.9</td>
</tr>
<tr>
<td>Marginal effect¶</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6 months</td>
<td>53.3±7.8</td>
<td>52.3±9.0</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5 years</td>
<td>52.4±8.4</td>
<td>50.8±10.5</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Between-center variance</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD.
† Treatment effect size was determined by comparing groups using general linear models with adjustments for the baseline mean score and for the following covariates: age; sex; race; severity of varicose veins; prior varicose vein treatments; and smoking status. Data were used to estimate effect sizes and interactions, and any missing data were assumed to be missing at random.
‡ The comparison between the foam sclerotherapy group and the surgery group includes participants from strata A and B; the comparison between the laser ablation group and between the foam sclerotherapy group include participants from stratum A only.
§ Scores on the AVVQ range from 0 to 100, with lower scores indicating a better quality of life.
¶ The marginal effect is the average effect of the intervention across all time points for which outcome data are reported.
‖ P<0.001.
** Scores on the EQ-5D questionnaire range from −0.594 to 1, with higher scores indicating a better quality of life.
†† The SF-36 physical component summary (PCS) and mental component summary (MCS) each consists of the sum of four individual domains; each summary score ranges from 0 to 100, with higher scores indicating greater well-being.
Five-Year Outcomes of Treatments for Varicose Veins

The participant-reported VAS score was 2.6±2.2 with laser ablation, 3.2±2.5 with foam sclerotherapy, and 2.4±2.3 with surgery (effect size for laser ablation vs. foam sclerotherapy, −0.79; 95% CI, −1.24 to −0.34; and for surgery vs. foam sclerotherapy, −0.74; 95% CI, −1.12 to −0.36). Similar scores were noted for the nurse-reported VAS scores. Venous Clinical Severity Score assessments were better at 5 years than at baseline in all groups. Five years after treatment, there were no significant differences between the treatments. The rates of complete success with respect to truncal-vein ablation at 5 years were 64.0% with laser ablation, 33.3% with foam sclerotherapy, and 75.9% with surgery. (Additional details on effect sizes are provided in Tables S12 and S13 in the Supplementary Appendix.)

The individual patient cost and utility data for the three-way analysis and two-way analysis, performed according to the intention-to-treat principle, are summarized in Tables S14 and S15, respectively, in the Supplementary Appendix. In the adjusted trial-data–based cost-effectiveness analysis, treatment with laser ablation had the highest chance (71.6%) of being cost-effective in the three-way comparison, at a ceiling willingness-to-pay ratio of £20,000 ($28,433) per QALY gained. In the two-way comparison, the incremental cost-effectiveness ratio for surgery compared with foam sclerotherapy was below the willingness-to-pay threshold in 83.3% of the bootstrapped samples (Table S16 in the Supplementary Appendix). There were no significant differences in QALYs among the treatment methods.

Discussion

In this large, multicenter trial comparing surgery, laser ablation, and foam sclerotherapy for the treatment of primary varicose veins, quality of life was better at 5 years than at baseline in all groups. Five years after treatment, there were significant differences between the treatments with respect to disease-specific quality of life. The AVVQ scores were better among participants treated with laser ablation or surgery than among those treated with foam sclerotherapy, with effect sizes of 2.86 and 2.60, respectively. Quality of life was similar in the laser ablation and surgery groups. The 5-year cost-effectiveness results were determined by the participant-reported VAS score, the AVVQ, the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) physical component summary (PCS) and mental component summary (MCS), and the EuroQol EQ-5D questionnaire. The comparison between the foam sclerotherapy group and the surgery group includes participants from strata A and B, and the comparisons between the foam sclerotherapy group and between the foam sclerotherapy group and the laser ablation group include participants from stratum A only.

---

†† Scores on the SF-36 physical component summary (PCS) and mental component summary (MCS) each consist of the sum of four individual domains; each component scores range from 0 to 100, with higher scores indicating greater well-being.

‡‡ A score on the EQ-5D questionnaire ranges from −0.594 to 1, with higher scores indicating a better quality of life.

§§ The marginal effect is the average effect of the intervention across all time points for which outcome data are reported.
ly, laser ablation performed under a local anesthetic in a treatment-room setting had a 77% probability of being cost-effective up to a willingness-to-pay maximum of £20,000 ($28,433). There was considerable uncertainty in the two-way cost-effective analysis comparing foam sclerotherapy with surgery.

One previous, smaller study showed that at 5 years after treatment there was greater improvement in disease-specific quality of life (a secondary outcome) among patients treated with laser ablation than among those treated with foam sclerotherapy, but no difference in disease-specific quality of life was observed between patients who underwent foam sclerotherapy and those who underwent surgery.\(^{16}\) The differences in quality of life observed in our study are likely to relate to the fact that the presence of varicose veins at 5 years was less and extent worse among those who do not undergo lasera blation and surgery groups than in the foam sclerotherapy group, because disease-specific quality of life has previously been shown to be worse among those who have recurrent disease.\(^{16}\) In contrast, more patients in this study with varicose veins at 5 years were less and extent worse among those who do not undergo laser ablation and surgery groups than in the foam sclerotherapy group, because disease-specific quality of life has previously been shown to be worse among those who have recurrent disease.\(^{16}\) In contrast, more patients in this study with varicose veins at 5 years were less and extent worse among those who do not undergo laser ablation and surgery groups than in the foam sclerotherapy group, because disease-specific quality of life has previously been shown to be worse among those who have recurrent disease.\(^{16}\) In contrast, more patients in this study with varicose veins at 5 years were less and extent worse among those who do not undergo laser ablation and surgery groups than in the foam sclerotherapy group, because disease-specific quality of life has previously been shown to be worse among those who have recurrent disease.\(^{16}\)

### Table 3. Model-Based Incremental Cost-Effectiveness Results over a 5-Year Period.\(^*\)

<table>
<thead>
<tr>
<th>Model-Based Analysis</th>
<th>Mean Cost</th>
<th>Incremental Cost†</th>
<th>Mean QALYs</th>
<th>Mean Incremental QALYs (2.5th to 97.5th Percentile) †</th>
<th>ICER GBP (USD)</th>
<th>Probability of Cost-Effectiveness‡ percent at £20,000</th>
<th>Probability of Cost-Effectiveness‡ percent at £30,000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Three-way</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foam sclerotherapy</td>
<td>777 (1,105)</td>
<td>—</td>
<td>4.002</td>
<td>—</td>
<td>—</td>
<td>16.4</td>
<td>14.1</td>
</tr>
<tr>
<td>Laser ablation</td>
<td>1,237 (1,759)</td>
<td>460 (269 to 650) [654]</td>
<td>4.116</td>
<td>0.113 (−0.083 to 0.308)</td>
<td>3,780 (5,407)</td>
<td>777.2</td>
<td>77.5</td>
</tr>
<tr>
<td>Surgery</td>
<td>1,527 (2,171)</td>
<td>289 (67 to 508) [411]</td>
<td>4.057</td>
<td>−0.059 (−0.180 to 0.063)</td>
<td>Dominated‡§</td>
<td>6.4</td>
<td>8.1</td>
</tr>
<tr>
<td><strong>Two-way</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foam sclerotherapy</td>
<td>750 (1,066)</td>
<td>—</td>
<td>4.041</td>
<td>—</td>
<td>—</td>
<td>45.5</td>
<td>35.6</td>
</tr>
<tr>
<td>Surgery</td>
<td>1,487 (2,114)</td>
<td>737 (557 to 915) [1,048]</td>
<td>4.083</td>
<td>0.042 (−0.050 to 0.133)</td>
<td>17,554 (24,956)</td>
<td>54.5</td>
<td>64.5</td>
</tr>
</tbody>
</table>

* Costs were converted to U.S. dollars using the Organization for Economic Cooperation and Development (OECD) purchasing power parities for 2017 (£0.703402 equivalent to U.S. $1). GBP denotes British pound sterling, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, and USD U.S. dollar.

† Shown are 2.5th and 97.5th percentiles of 10,000 Monte Carlo simulations of the incremental costs and effects.

‡ Values are the proportion of simulated incremental costs and effects favoring each treatment at the incremental cost-effectiveness thresholds of £20,000 and £30,000 per QALY gained.

§ Surgery was deemed to be dominated (i.e., less effective and more costly than laser ablation).
previously reported model-based estimates derived from an existing network meta-analysis of trials.\textsuperscript{17,18} This previous meta-analysis included eight trials, the majority of which had less than 3 years of follow-up.\textsuperscript{29} Other Markov models have also shown laser ablation to have the highest chance of being cost-effective,\textsuperscript{30,31} whereas one has favored foam sclerotherapy.\textsuperscript{32} The model-based two-way comparison indicated that surgery cost considerably more than foam sclerotherapy and generated a small, nonsignificant QALY gain. The magnitude of the QALY gain was sensitive to the analysis method, in that it was larger in the two-way trial-data–based analysis than in the three-way analysis, although it was still nonsignificant in the two-way analysis. The larger QALY gain in the two-way analysis as compared with the three-way analysis is partly explained by more unrelated deaths occurring in the foam sclerotherapy group during follow-up.

Limitations of our study include the lack of a sham procedure and the fact that patients and assessors were aware of the treatments. There was a substantial amount of missing data at 5 years, although the response rate with respect to participant-reported outcomes was higher than anticipated.

In summary, this large, multicenter trial comparing the clinical effectiveness of laser ablation, foam sclerotherapy, and surgery for the treatment of varicose veins showed that in all three groups, quality of life 5 years after treatment was improved from baseline. However, there were clinically important between-group differences in disease-specific quality of life that favored laser ablation and surgery over foam sclerotherapy. Laser ablation was similar to surgery with respect to quality of life and of the three treatments had the highest chance of being cost-effective.

The views and opinions expressed are those of the authors and not necessarily those of the National Institute for Health Research (NIHR) or the Department of Health and Social Care.

**APPENDIX**

The authors’ affiliations are as follows: the Institute of Cardiovascular Research, University of Glasgow (J.B.), and the Institute of Applied Health Research, Nursing, Midwifery, and Allied Health Professions Research Unit, Glasgow Caledonian University (A.E.), Glasgow, the Health Services Research Unit (D.C., S.C.C., G.M., C.R.R., M.K.C.) and the Health Economics Research Unit (M.D., G.S., E.T.), University of Aberdeen, and the Department of Vascular Surgery, NHS Grampian, Aberdeen Royal Infirmary (P.B.), Aberdeen, the Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh (J.N.), the School of Medicine, Medical and Biological Sciences, University of St. Andrews, St. Andrews (J.M.B.), the Department of Vascular Surgery, Royal Devon and Exeter Hospital, Exeter (B.C.), the Department of Vascular Surgery, Hull Royal Infirmary, Hull (I.C.), the School of Surgery, University of Leeds (M.G.), and Vascular Surgery, St. James University Hospital (J.S.), Leeds, Vascular Surgery, Gloucestershire Royal Hospital, Gloucester (J.E.), Vascular Surgery, Freeman Hospital, Newcastle upon Tyne (T.L.), the Vascular Surgical Unit, Royal Bournemouth Hospital, Bournemouth (S.A.B.), and the School of Health Sciences, City University of London, London (J.F.) — all in the United Kingdom.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

Supported by the NIHR Health Technology Assessment Program (Project number 06/45/02). The Health Services Research Unit is core-funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorate.

No potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Janice Cruden for secretarial support and data management; Glady McPherson, Mark Forrest, and the programming team at the Centre for Healthcare Randomized Trials; members of the Project Management Group for ongoing advice and support of the trial; the independent members of the trial steering committee and data and safety monitoring committee; and the staff at recruitment sites who facilitated recruitment, treatment, and follow-up of trial participants.


23. EQ-5D. Rotterdam, the Netherlands: EuroQol (http://www.euroqol.org/).


Copyright © 2019 Massachusetts Medical Society.